|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Buyukcelik A, Yalcin B and Utkan G:
Multidisciplinary management of lung cancer. N Engl J Med.
350:2008–2010; author reply 2008–2010 2004. PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cech TR and Steitz JA: The noncoding RNA
revolution-trashing old rules to forge new ones. Cell. 157:77–94.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guttman M, Russell P, Ingolia NT, Weissman
JS and Lander ES: Ribosome profiling provides evidence that large
noncoding RNAs do not encode proteins. Cell. 154:240–251. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY,
Gong W and Quan ZW: Long non-coding RNA CCAT1 promotes gallbladder
cancer development via negative modulation of miRNA-218-5p. Cell
Death Dis. 6:e15832015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu Q, Deng F, Qin Y, Zhao Z, Wu Z, Xing Z,
Ji A and Wang QJ: Long non-coding RNA regulation of
epithelial-mesenchymal transition in cancer metastasis. Cell Death
Dis. 7:e22542016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li W, Sun M, Zang C, Ma P, He J, Zhang M,
Huang Z, Ding Y and Shu Y: Upregulated long non-coding RNA
AGAP2-AS1 represses LATS2 and KLF2 expression through interacting
with EZH2 and LSD1 in non-small-cell lung cancer cells. Cell Death
Dis. 7:e22252016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun X, Du P, Yuan W, Du Z, Yu M, Yu X and
Hu T: Long non-coding RNA HOTAIR regulates cyclin J via inhibition
of microRNA-205 expression in bladder cancer. Cell Death Dis.
6:e19072015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng N, Cai W, Ren S, Li X, Wang Q, Pan
H, Zhao M, Li J, Zhang Y, Zhao C, et al: Long non-coding RNA UCA1
induces non-T790M acquired resistance to EGFR-TKIs by activating
the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
Oncotarget. 6:23582–23593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang EB, Yin DD, Sun M, Kong R, Liu XH,
You LH, Han L, Xia R, Wang KM, Yang JS, et al: P53-regulated long
non-coding RNA TUG1 affects cell proliferation in human non-small
cell lung cancer, partly through epigenetically regulating HOXB7
expression. Cell Death Dis. 5:e12432014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang NS, Chi YY, Xue JY, Liu MY, Huang S,
Mo M, Zhou SL and Wu J: Long non-coding RNA metastasis associated
in lung adenocarcinoma transcript 1 (MALAT1) interacts with
estrogen receptor and predicted poor survival in breast cancer.
Oncotarget. 7:37957–37965. 2016.PubMed/NCBI
|
|
13
|
Qi HL, Li CS, Qian CW, Xiao YS, Yuan YF,
Liu QY and Liu ZS: The long noncoding RNA, EGFR-AS1, a target of
GHR, increases the expression of EGFR in hepatocellular carcinoma.
Tumour Biol. 37:1079–1089. 2016. View Article : Google Scholar
|
|
14
|
Tan DSW, Chong FT, Leong HS, Toh SY, Lau
DP, Kwang XL, Zhang X, Sundaram GM, Tan GS, Chang MM, et al: Long
noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor
addiction and modulates treatment response in squamous cell
carcinoma. Nat Med. 23:1167–1175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang Q, Cai JB, Dong RZ, Liu LX, Zhang C,
Zhang PF, Zou H, Xie N, Zhang L, Zhang XY, et al: Mortalin promotes
cell proliferation and epithelial mesenchymal transition of
intrahepatic cholangiocarcinoma cells in vitro. J Clin Pathol.
70:677–683. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR,
Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, et al: Galectin-1
induces hepato-cellular carcinoma EMT and sorafenib resistance by
activating FAK/PI3K/AKT signaling. Cell Death Dis. 7:e22012016.
View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
18
|
Zhao FY, Han J, Chen XW, Wang J, Wang XD,
Sun JG and Chen ZT: miR-223 enhances the sensitivity of non-small
cell lung cancer cells to erlotinib by targeting the insulin-like
growth factor-1 receptor. Int J Mol Med. 38:183–191. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X,
Peng L, Sun J and Chen Z: miR-223 reverses the resistance of
EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. Int J Oncol.
48:1855–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Richards EJ, Permuth-Wey J, Li Y, Chen YA,
Coppola D, Reid BM, Lin HY, Teer JK, Berchuck A, Birrer MJ, et al:
A functional variant in HOXA11-AS, a novel long non-coding RNA,
inhibits the oncogenic phenotype of epithelial ovarian cancer.
Oncotarget. 6:34745–34757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Q, Zhang J, Liu Y, Zhang W, Zhou J,
Duan R, Pu P, Kang C and Han L: A novel cell cycle-associated
lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA
transcript and is a biomarker of progression in glioma. Cancer
Lett. 373:251–259. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong J, Liu Y, Liao W, Liu R, Shi P and
Wang L: miRNA-223 is a potential diagnostic and prognostic marker
for osteosarcoma. J Bone Oncol. 5:74–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Werner H and Sarfstein R: Transcriptional
and epigenetic control of IGF1R gene expression: Implications in
metabolism and cancer. Growth Horm IGF Res. 24:112–118. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ball MW, Bezerra SM, Chaux A, Faraj SF,
Gonzalez-Roibon N, Munari E, Sharma R, Bivalacqua TJ, Netto GJ and
Burnett AL: Overexpression of insulin-like growth factor-1 receptor
is associated wth penile cancer progression. Urology. 92:51–56.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park E, Park SY, Kim H, Sun PL, Jin Y, Cho
SK, Kim K, Lee CT and Chung JH: Membranous insulin-like growth
factor-1 receptor (IGF1R) expression is predictive of poor
prognosis in patients with epidermal growth factor receptor
(EGFR)-mutant lung adenocarcinoma. J Pathol Transl Med. 49:382–388.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rota LM, Albanito L, Shin ME, Goyeneche
CL, Shushanov S, Gallagher EJ, LeRoith D, Lazzarino DA and Wood TL:
IGF1R inhibition in mammary epithelia promotes canonical Wnt
signaling and Wnt1-driven tumors. Cancer Res. 74:5668–5679. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Q, Zhang J, Cui Q, Li X, Gao G, Wang
Y, Xu Y and Gao X: GSK1904529A, an insulin-like growth factor-1
receptor inhibitor, inhibits glioma tumor growth, induces apoptosis
and inhibits migration. Mol Med Rep. 12:3381–3385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Puzanov I, Lindsay CR, Goff L, Sosman J,
Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A,
et al: A phase I study of continuous oral dosing of OSI-906, a dual
inhibitor of insulin-like growth factor-1 and insulin receptors, in
patients with advanced solid tumors. Clin Cancer Res. 21:701–711.
2015. View Article : Google Scholar
|
|
29
|
Di Cosimo S, Sathyanarayanan S, Bendell
JC, Cervantes A, Stein MN, Braña I, Roda D, Haines BB, Zhang T,
Winter CG, et al: Combination of the mTOR inhibitor ridaforolimus
and the anti-IGF1R monoclonal antibody dalotuzumab: Preclinical
characterization and phase I clinical trial. Clin Cancer Res.
21:49–59. 2015. View Article : Google Scholar
|
|
30
|
Nurwidya F, Takahashi F, Kobayashi I,
Murakami A, Kato M, Minakata K, Nara T, Hashimoto M, Yagishita S,
Baskoro H, et al: Treatment with insulin-like growth factor 1
receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal
transition in non-small cell lung cancer. Biochem Biophys Res
Commun. 455:332–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park JH, Choi YJ, Kim SY, Lee JE, Sung KJ,
Park S, Kim WS, Song JS, Choi CM, Sung YH, et al: Activation of the
IGF1R pathway potentially mediates acquired resistance to
mutant-selective 3rd-generation EGF receptor tyrosine kinase
inhibitors in advanced non-small cell lung cancer. Oncotarget.
7:22005–22015. 2016.PubMed/NCBI
|
